Cosentyx(secukinumab)
Cosentyx (secukinumab) is an antibody pharmaceutical. Secukinumab was first approved as Cosentyx on 2015-01-14. It is used to treat ankylosing spondylitis and psoriatic arthritis in the USA. It has been approved in Europe to treat ankylosing spondylitis, psoriasis, and psoriatic arthritis. The pharmaceutical is active against interleukin-17A.
Download report
Favorite
Novartis Pharmaceuticals
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Cosentyx
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Secukinumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Cosentyx | secukinumab | Novartis Pharmaceuticals Corporation | N-125504 RX | 2015-01-21 | 4 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cosentyx | Biologic Licensing Application | 2020-06-16 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| ankylosing spondylitis | EFO_0003898 | D013167 | M45 |
| psoriatic arthritis | EFO_0003778 | D015535 | L40.5 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
193 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 5 | 8 | 27 | 16 | 14 | 69 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | 1 | 4 | 14 | 4 | 4 | 27 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 2 | 9 | 5 | 1 | 17 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 3 | 3 | 1 | — | 7 |
| Healthy volunteers/patients | — | 4 | 1 | — | 1 | — | 5 | ||
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | 2 | — | 2 |
| Spondylarthritis | D025241 | — | — | 1 | 1 | — | 2 | ||
| Lamellar ichthyosis | D017490 | Q80 | — | 1 | — | 1 | — | 2 | |
| Inflammation | D007249 | — | — | — | 1 | — | 1 | ||
| Biopsy | D001706 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hidradenitis suppurativa | D017497 | L73.2 | 1 | — | 3 | — | 1 | 5 | |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | — | 4 | — | — | 4 |
| Giant cell arteritis | D013700 | EFO_1001209 | M31.6 | — | 1 | 2 | — | — | 3 |
| Lupus nephritis | D008181 | EFO_0005761 | — | — | 2 | — | — | 2 | |
| Juvenile arthritis | D001171 | EFO_0002609 | M08 | — | — | 2 | — | — | 2 |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | — | 1 | 1 | — | — | 2 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | 1 | — | — | 1 | |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | 1 | — | — | 1 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | 1 | — | — | 1 |
| Spondylarthropathies | D025242 | EFO_0000706 | M47 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 2 | — | — | 1 | 3 |
| Pyoderma gangrenosum | D017511 | EFO_0006835 | L88 | 1 | 2 | — | — | — | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 2 | — | — | — | 2 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 2 | — | — | — | 2 |
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 | |
| Rosacea | D012393 | L71 | 1 | 1 | — | — | — | 1 | |
| Lichen planus | D008010 | L43 | — | 1 | — | — | — | 1 | |
| Discoid lupus erythematosus | D008179 | L93.0 | — | 1 | — | — | — | 1 | |
| Necrobiosis lipoidica | D009335 | — | 1 | — | — | — | 1 | ||
| Alopecia areata | D000506 | EFO_0004192 | L63 | — | 1 | — | — | — | 1 |
Show 13 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SECUKINUMAB |
| INN | secukinumab |
| Description | Secukinumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 875356-43-7 |
| RxCUI | 1599788 |
| ChEMBL ID | CHEMBL1743068 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09029 |
| UNII ID | DLG4EML025 (ChemIDplus, GSRS) |
Target
Agency Approved
IL17A
IL17A
Organism
Homo sapiens
Gene name
IL17A
Gene synonyms
CTLA8, IL17
NCBI Gene ID
Protein name
interleukin-17A
Protein synonyms
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, cytotoxic T-lymphocyte-associated protein 8, interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8), interleukin-17
Uniprot ID
Mouse ortholog
Il17a (16171)
interleukin-17A (Q62386)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Cosentyx - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,527 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,531 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more